FGF21 and Alzheimer disease: Wang et al. has developed PEGylated liposomes modified with BV2 microglial cell membranes (hFGF-21@BCM-LIP), enabling targeted delivery of liver-derived FGF-21 to AD pathological microenvironments via subcutaneous injection [99].